StanleyRabanFrankelMD

Oncology • Park City, UT

Hematologic Oncology

Physician

Join to view full profile

Dr. Frankel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frankel's full profile

Already have an account?

Office
5211B Cove Canyon Drive
Park City, UT 84098
Phone+1 646-397-7826

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1985 - 1988
Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1986 - 2026
UT State Medical License 2021 - 2026
MD State Medical License 1974 - 2016
NJ State Medical License 2001 - 2011
DC State Medical License 1994 - 2002
American Board of Internal Medicine Internal Medicine

Clinical Trials

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Start of enrollment: 2000 Jul 01
Completed
Phase 3
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2000 Dec 01
Completed
Phase 2
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2000 Dec 01
Completed
Phase 3
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2001 Jul 01
Completed
Phase 3
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

49 citations
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo, Kathryn J. Newhall, Angus M. Sinclair
Plos One. 2015-08-25
138 citations
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall
Blood. 2014-01-23
47 citations
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid recepto...
Reinhard Dummer, Marc Beyer, Kenneth B. Hymes, Mirjam T. Epping, René Bernards
Leukemia & Lymphoma. 2012-01-12

Press Mentions

IMV Inc. Announces Second Quarter 2021 Financial and Operational ResultsAugust 11th, 2021
Intercept Retools C-suite with a Pair of Newcomers; Charles Ryan Moves Past Alzheimer's Flops with Another CEO ChallengeJune 11th, 2021
BioSpace Movers & Shakers, June 11June 10th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member